ASTX727 in Patients with Hepatic Impairment

A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
27 patients (estimated)
Sponsors
Taiho Oncology, Inc.
Tags
Chemotherapy, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2117
NCT Identifier
NCT04953910

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.